Print Magazine
Brussels Morning Newspaper
Monday, June 27, 2022
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Europe With Transparency
    • Sustainable Perspective
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home EU Institutions Commission

Commission signs deal for new COVID-19 antibody treatment

Marta Pacheco by Marta Pacheco
29 July 2021
in Commission
Brussels,,Belgium,-,June,22,,2019:,Berlaymont,European,Commision,Building
Share on FacebookShare on Twitter

Brussels (Brussels Morning) The European Commission recently signed a joint procurement contract with the Glaxo Smith Kline (GSK) pharmaceutical company for the supply of sotrovimab, an investigational monoclonal antibody therapy, developed in collaboration with VIR biotechnology. 

The sotrovimab antibody is currently under rolling review by the European Medicines Agency (EMA), the process used to speed up assessments of promising medicinal products in the midst of a public health emergency.

The procurement contract, which was signed on 28 July, is part of the initial portfolio of five promising therapeutics that the Commission announced in June 2021. 

Other monoclonal antibodies currently being assessed by the EMA include the combination of bamlanivimab and etesevimab, the combination of casirivimab and imdevimab and, finally, regdanivimab.

In total, 16 EU countries have signed procurement orders for the purchase of up to 220,000 treatments, the Commission announced.

In June, the EU executive appealed to companies and organisations working on the development of compounds in new or repurposed medicines for COVID19 therapeutics. The aim was to identify and connect the companies concerned and to support and encourage overall production planning.

By October, the Commission intends to have drawn up a portfolio of 10 potential COVID-19 therapeutics.

Treating mild symptoms

Sotrovimab can be used in treating coronavirus patients with mild symptoms – those who do not require supplemental oxygen, but who are at high risk for severe COVID-19. 

Ongoing studies suggest that early treatment means fewer patients develop more severe symptoms requiring hospitalisation or admission to intensive care units. 

“We committed in our COVID-19 Therapeutics Strategy to have at least three new therapeutics authorised by October. We are now delivering a second framework contract that brings monoclonal antibodies treatments to patients”,Stella Kyriakides, Commissioner for Health and Food Safety, declared.

Monoclonal antibodies are proteins conceived in the laboratory that mimic the immune system’s ability to fight the coronavirus. They attach to the spike protein and thus block the virus from attaching to the human cells. 

To date, the Commission has concluded nearly 200 contracts for different medical countermeasures worth over 12 billion euro. 

Under the framework of the current contract with GSK, EU countries will be allowed to purchase sotrovimab if and when needed, once it has received either emergency use authorisation in the member state concerned or a (conditional) marketing authorisation at EU level from the EMA.

“Alongside vaccines, safe and effective therapeutics will play a pivotal role in Europe’s return to a new normal”, Kyriakides observed.

Tags: Biweekly MartaBrussels LatestEuropean Commission (LAH)Main-Slider

Latest post

Mont,De,Marsan,Landes,France,05,17,2019,Eurofighter,Typhoon

German MTU hopes for new contracts in Luftwaffe overhaul

1 day ago
Flags,Of,Moldova,European,Union,And,Ukraine

Supporting Moldova means supporting stability in Ukraine

2 days ago

Most Read

  • These are the 10 highest paying jobs in the Europe in 2022

    These are the 10 highest paying jobs in the Europe in 2022

    0 shares
    Share 0 Tweet 0
  • What Are The Highest Paying Jobs In Luxembourg?

    0 shares
    Share 0 Tweet 0
  • Energy Recovery Fund

    0 shares
    Share 0 Tweet 0
  • What Are The Highest Paying Jobs In Finland?

    0 shares
    Share 0 Tweet 0
  • A taste of Croatian flavors of the diplomacy in Brussels

    0 shares
    Share 0 Tweet 0
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Belgium News
  • Brussels
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • EU Institutions
    • Parliament
    • Commission
    • Council
  • Europe
  • World
  • Member States
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • The American Angle
    • Southeast Europe
  • Print Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT